News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoViricides, Inc. (NNVC.PK) Reports Its Oral FluCide® Anti-Influenza Drug Candidates Are Superior to Oral Oseltamivir (TamiFlu®) in H1N1 Influenza Lethal Infection Model


9/10/2012 9:35:02 AM

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that oral administration of its FluCide™ anti-influenza drug candidates provided clinically important disease protection in a lethal animal model of influenza infection. Moreover, the FluCide™ candidates were superior to oral oseltamivir (Tamiflu®, Roche), a current standard of care for influenza, in all parameters evaluated.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES